Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair [MAPK inhibitors]
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × A375_MAPKi-0D vs 3 × A375_MAPKi-2D vs 3 × A375_MAPKi-9D vs 3 × A375_DMSO-0DGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repairNAR cancer · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE232709_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA973618 and SRA study SRP438226. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7372169 A375_MAPKi-0D_R1 A375_MAPKi-0D
- GSM7372170 A375_MAPKi-0D_R2 A375_MAPKi-0D
- GSM7372171 A375_MAPKi-0D_R3 A375_MAPKi-0D
- GSM7372172 A375_MAPKi-2D_R1 A375_MAPKi-2D
- GSM7372173 A375_MAPKi-2D_R2 A375_MAPKi-2D
- GSM7372174 A375_MAPKi-2D_R3 A375_MAPKi-2D
- GSM7372175 A375_MAPKi-9D_R1 A375_MAPKi-9D
- GSM7372176 A375_MAPKi-9D_R2 A375_MAPKi-9D
- GSM7372177 A375_MAPKi-9D_R3 A375_MAPKi-9D
- GSM7372178 A375_DMSO-0D_R1 A375_DMSO-0D
- GSM7372179 A375_DMSO-0D_R2 A375_DMSO-0D
- GSM7372180 A375_DMSO-0D_R3 A375_DMSO-0D
- GSE233121 Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair [QuantSeq_Q_siCTU2] 72 samples shares mapk, metabolism-dependent, secondary, anti-mapk, therapy, repair
- GSE233122 Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair [RNAseq_siRNA_MAPKi] 36 samples shares mapk, metabolism-dependent, secondary, anti-mapk, therapy, repair
- GSE289746 Combined therapy with DR5- targeting antibody-drug conjugate and CDK inhibitors as a novel strategy for advanced MSS and MSI-H colorectal cancer 12 samples shares inhibitors, therapy
- GSE270287 DNA damage induced by G-quadruplex ligand PyBI and its synthetic lethality with DNA repair inhibitors in cancer cells 19 samples shares inhibitors, repair
- GSE280280 Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory circuits During Response to MAPK Inhibition in BRAF-mutant colorectal cancer 36 samples shares mapk
- GSE303051 Prolonged KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals Therapeutic Opportunities. 30 samples shares mapk
- GSE262667 SRSF7-mediated Alternative Splicing of USO1 Promotes Hepatocellular Carcinoma by Activating the MAPK/ERK1-ELK1 Pathway 19 samples shares mapk
- GSE287599 Multi-omics Dissection of MAPK-driven Senescence Unveils Therapeutic Vulnerabilities in KIAA1549::BRAF-fusion Pediatric Low-Grade Glioma Models 15 samples shares mapk
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.